Literature DB >> 23103057

Chronic administration of the Y2 receptor antagonist, JNJ-31020028, induced anti-depressant like-behaviors in olfactory bulbectomized rat.

J C Morales-Medina1, Y Dumont, P Bonaventure, R Quirion.   

Abstract

Recent studies from our groups have shown that BIIE0246, a Y2 receptor antagonist, has antidepressant effect in olfactory bulbectomized (OBX) rat. However, its complex structure and high molecular weight limit its usefulness as an in vivo pharmacological tool. Alternatively, the novel and brain penetrant Y2 receptor antagonist, JNJ-31020028 is a useful tool to investigate the in vivo function of the Y2 receptor. In the present study, we evaluated the effect of chronic intracerebroventricular (icv) administration of JNJ-31020028 in a battery of behavioral tests in an animal model that mimics several deficits observed in the human depression, the OBX rat. Chronic administration of JNJ-31020028 induced a decrease in immobility time in the forced swim test in OBX while had no effect in control animals. Additionally, it decreased number of grooming events in OBX animals, but had no effects on some other behavioral deficits observed such as rearing and hyperlocomotion. Furthermore, JNJ-31020028 had no effect on behavior tests that are commonly used to evaluate anxiety, namely the social interaction test in both OBX and control animals. These data indicate that similar to BIIE0246, JNJ-31020028 also has antidepressant like effects in the OBX model. Crown
Copyright © 2012. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103057     DOI: 10.1016/j.npep.2012.09.009

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  8 in total

1.  Administration of the Y2 receptor agonist PYY3-36 in mice induces multiple behavioral changes relevant to schizophrenia.

Authors:  Ulrike Stadlbauer; Wolfgang Langhans; Urs Meyer
Journal:  Neuropsychopharmacology       Date:  2013-06-10       Impact factor: 7.853

Review 2.  Ligands of the neuropeptide Y Y2 receptor.

Authors:  Gopi Kumar Mittapalli; Edward Roberts
Journal:  Bioorg Med Chem Lett       Date:  2013-12-04       Impact factor: 2.823

3.  Bacopa monnieri ameliorates memory deficits in olfactory bulbectomized mice: possible involvement of glutamatergic and cholinergic systems.

Authors:  Xoan Thi Le; Hang Thi Nguyet Pham; Phuong Thi Do; Hironori Fujiwara; Ken Tanaka; Feng Li; Tai Van Nguyen; Khoi Minh Nguyen; Kinzo Matsumoto
Journal:  Neurochem Res       Date:  2013-08-15       Impact factor: 3.996

4.  Targeting the Neuropeptide Y System in Stress-related Psychiatric Disorders.

Authors:  Nicole M Enman; Esther L Sabban; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Neurobiol Stress       Date:  2015-01-01

5.  Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence.

Authors:  Helena Domin; Bernadeta Szewczyk; Bartłomiej Pochwat; Monika Woźniak; Maria Śmiałowska
Journal:  Psychopharmacology (Berl)       Date:  2016-12-14       Impact factor: 4.530

6.  NPY Receptor 2 Mediates NPY Antidepressant Effect in the mPFC of LPS Rat by Suppressing NLRP3 Signaling Pathway.

Authors:  Wenjiao Wang; Tao Xu; Xinyue Chen; Kemeng Dong; Chunkai Du; Jing Sun; Cuige Shi; Xiaoxiao Li; Yutao Yang; Hui Li; Zhi-Qing David Xu
Journal:  Mediators Inflamm       Date:  2019-05-15       Impact factor: 4.711

Review 7.  Sex differences in antidepressant efficacy.

Authors:  Tara A LeGates; Mark D Kvarta; Scott M Thompson
Journal:  Neuropsychopharmacology       Date:  2018-07-20       Impact factor: 7.853

8.  Acupuncture Stimulation Attenuates Impaired Emotional-Like Behaviors and Activation of the Noradrenergic System during Protracted Abstinence following Chronic Morphine Exposure in Rats.

Authors:  Bombi Lee; Bong-Jun Sur; Insop Shim; Dae-Hyun Hahm; Hyejung Lee
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-09       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.